The Cannigma

APRIL 12, 2023

MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

JUNE 29, 2021

We look forward to his expertise as we expand our mental health analytical platform and enter clinical trials. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. Ehave, Inc.

Clinical Trials 105

Clinical Trials Research and Development Data Patients 105

Cannabis Law Report

JUNE 21, 2021

Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Advantages of Data, Macro, and Micro. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

NORML

APRIL 30, 2020

The call for comments, posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”

Chronic Pain 346

Chronic Pain Clinical Trials Data Patients 346

NORML

MARCH 30, 2020

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. However, this data was based solely on preclinical findings.

CBD 300

CBD Clinical Trials Data Treatment 300

Cannabis Law Report

JUNE 4, 2021

Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Clinical trial information: NCT03276572 ( [link] ). NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. AIkido Pharma Inc.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

OCTOBER 28, 2021

Psymposia report… O n Sep 23, 2021, Psymposia staff received an email from the personal email account of Mark Haden — the former Executive Director of psychedelic nonprofit MAPS Canada and current Director of Clinical Trials for Psygen Inc. MAPS Canada’s Data Breach Foreshadows Corporadelic Future.

Data 52

Data Clinical Trials Events Medicine 52

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A Visit www.floragrowth.ca

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”. Eurofins is testing for life.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JULY 27, 2021

His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz, a clinical psychologist, led the development of the ORR as a postdoctoral research fellow at Johns Hopkins University. About Realm of Caring.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials 194

Clinical Trials Chronic Pain Data Treatment 194

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. All imaging and behavioral data will be accessible to the public after the study is complete. What Is an MRI?

Clinical Trials 91

Clinical Trials Research and Development Data Collective 91

Veriheal

JANUARY 11, 2023

Not only this, but Gaize recently completed the largest clinical trial into cannabis impairment , and the results are set to transform the realm of workplace and road safety. Keen to learn more about the trial and Gaize’s innovative product, I asked CEO Ken Fichtler some questions. Here’s what he had to say.

Clinical Trials 97

Clinical Trials THC Data Safety 97

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. For further information please visit out website: www.globalwellnessstrategies.com. from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

MAY 10, 2022

Data obtained through a freedom of information request to drugs regulator the Therapeutic Goods Administration (TGA) revealed the age of those prescribed the drugs, the reason for prescribing, and the state or territory where the prescription was made. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

JULY 28, 2021

More information about the organization is available at [link]. Reporting to the Regulatory Affairs Manager, the RPS supports functions related to tracking regulatory information and document styling and publishing in eCTD format for regulatory submissions. MAPS PBC is committed to the evolution of psychedelic healing modalities.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

Cannabis Law Report

AUGUST 17, 2021

Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Building the Data Backend. For more information, visit the company’s website or download their investor presentation. Disclaimer.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. Clinical Trial Sample Size. Missing Information. While lengthy, there is a surprising amount of missing information in the study.

Research and Development 95

Research and Development Clinical Trials Consumption Patients 95

Cannabis Law Report

JULY 7, 2021

What we understand from our insight data is that physicians are very willing to look at medical cannabis as an option,” Faltischek told MarketWatch, noting that in Germany doctors first explore options in traditional medicine before cannabis. We also believe that there’s a large amount of observational data.”. Source: [link].

Clinical Trials 105

Clinical Trials Education Data Pharmaceutical 105

Cannabis Law Report

NOVEMBER 23, 2021

COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. Availability of other information about COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. World Health Organization (WHO).

THC 59

THC Clinical Trials Data Consumption 59

The Cannigma

FEBRUARY 2, 2021

“Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data,” lead investigator Professor Carsten Buhmann of the University Medical Center Hamburg-Eppendorf explained in a statement.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

DECEMBER 9, 2021

These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU. Forward-Looking Statements.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Otherside Farms

JANUARY 25, 2019

“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients. The findings have identified the potential for cannabinoids to reduce brain damage caused by stroke.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

JUNE 7, 2021

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website. For more information, visit www.mymd.com. FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66